. 2018 Sep;43(9):549–556.

Table 3.

Monitoring Parameters for PARP Inhibitors

PARP Inhibitor (Generic Name)	Indication for Monitoring	Labs and Monitoring Schedule
Niraparib³⁴	Bone marrow suppression AML/MDS	Monitor CBC weekly for first month, then monthly for the following 11 months, then periodically
	Cardiovascular events	Monitor BP and HR monthly for first year of therapy, then periodically
Olaparib³⁵	Bone marrow suppression AML/MDS	Monitor CBC at baseline, then monthly
	Pneumonitis	Monitor for signs and symptoms of pneumonitis
Rucaparib³⁷	Bone marrow suppression AML/MDS	Monitor CBC at baseline, then monthly

AML = acute myeloid leukemia; BP = blood pressure; CBC = complete blood count; HR = heart rate; MDS = myelodysplastic syndrome.